title: Effect Comparison of Both Iron Chelators on Outcomes, Iron Deposit, and Iron Transporters After Intracerebral Hemorrhage in Rats.
abstract: Iron overload plays a key role in brain injury after intracerebral hemorrhage (ICH). We explored the roles of ferric iron chelator-deferiprone (DFP)-and ferrous iron chelator-clioquinol (CQ)-in ICH rats through the outcomes, iron deposits, reactive oxygen species (ROS), brain water content, and related iron transporters. One hundred eight Sprague-Dawley rats received intra-striatal infusions of 0.5 U of type IV collagenase to establish ICH models. The rats were randomly assigned to the sham, vehicle, DFP, and CQ groups. We evaluated the outcomes, iron levels, brain water content, and ROS; meanwhile, immunohistochemistry and real-time quantitative polymerase chain reaction (RT-qPCR) were utilized to determine ferritin, transferrin, transferrin receptor, divalent metal transport 1 (DMT1), and ferroportin at 48 and 72 h, 7 and 14 days after surgery. Our results showed ICH induced iron overload, brain edema, ROS formation, and neurological deficits. Both iron chelators decreased iron levels; CQ improved the neurological outcome, attenuated brain edema, and ROS production. DFP reduced iron contents but not brain water content and ROS generation. DFP failed to improve the outcome. ICH initiated endogenous iron chelators and transporters, both exogenous iron chelators enhanced expression of transferrin and transferrin receptor. CQ enhanced expression of ferroportin but not DMT1, while DFP enhanced expression of DMT1 but not ferroportin. Ferrous iron contributed to brain injury, and binding ferrous iron can modestly improve outcome after ICH in rats. The exogenous ferrous iron chelator possibly functioned via endogenous ferrous iron transporters on ICH. Therefore, ferrous iron may be a promising target for ICH in future.
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China. wanggq08@126.com.
authors.forename: Gaiqing
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Weimin
authors.initials: W
authors.lastname: Hu
authors.affiliation: Department of Rehabilitation, Brain Hospital of Hunan Province, 2427 Furong Middle Road, Changsha, Hunan, 410007, China.
authors.forename: Qingping
authors.initials: Q
authors.lastname: Tang
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Xin-Gang
authors.initials: XG
authors.lastname: Sun
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Yanli
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Yin
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Xue
authors.affiliation: Department of Neurology, the Second Hospital, Shanxi Medical University, 382 Wuyi Avenue, Taiyuan, Shanxi, 030001, China.
authors.forename: Zhitang
authors.initials: Z
authors.lastname: Sun
mesh_terms: D000818:Animals; D001921:Brain / Q000473:pathology; D001929:Brain Edema / Q000188:drug therapy / Q000473:pathology; D027682:Cation Transport Proteins / Q000378:metabolism*; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D007464:Clioquinol / Q000494:pharmacology / Q000627:therapeutic use*; D000077543:Deferiprone; D005293:Ferritins / Q000378:metabolism; D006406:Hematoma / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D007150:Immunohistochemistry; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use*; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D016019:Survival Analysis; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome; D000098742:Ferroportin; D000099236:Solute Carrier Family 11, Member 2
chemical_list: D027682:Cation Transport Proteins; D007464:Clioquinol; D000077543:Deferiprone; D005293:Ferritins; D007501:Iron; D007502:Iron Chelating Agents; D011728:Pyridones; D017382:Reactive Oxygen Species; D014168:Transferrin; D000098742:Ferroportin; D000099236:Solute Carrier Family 11, Member 2
keywords: Clioquinol; Deferiprone; Intracerebral hemorrhage; Iron deposit; Iron transporters; Secondary brain injury